Analyst's Ratings : Boston Scientific Corporation (NYSE:BSX)

Mindy Sparks
November 14, 2017

Boston Scientific Corporation (BSX) have shown a high EPS growth of -2.80% in the last 5 years and has earnings rose of 241.40% yoy. The stock ended last trade at $28.45 a share and the price is up more than 31.53% so far this year. Amalgamated Bank now owns 165,040 shares valued at $4,814,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

In the market the company is trading down from yesterday's close of 28.46. The return on assets stands at 4.6%, Return on Equity now is 11.8% and the Return on Investment value is 5.1%. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93.

Deep diving into the technical levels for Boston Scientific Corp (BSX), we note that the equity now has a 14-day Commodity Channel Index (CCI) of 15.51. The value of the investment in BSX decreased from $70,108,000 to $67,254,000 a change of $2,854,000 quarter to quarter. As of the latest earnings report the EPS was $0.61 with 1.37B shares now outstanding. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.21 billion.

Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. Capital World Investors lifted its holdings in shares of Boston Scientific Corporation by 1.6% in the second quarter. Its sales stood at 1.90% a year on average in the period of last five years.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another domain, it was stolen and reposted in violation of USA and worldwide trademark and copyright law. The original version of this news story can be viewed at After a recent check, the 14-day RSIfor Boston Scientific Corp (BSX) is now at 47.16, the 7-day stands at 51.24, and the 3-day is sitting at 62.61.

Boston Scientific Corporation's average Book Value per Share Growth Rate was 16.1 percent during the past 12 months. Leerink Swann reaffirmed a buy rating on shares of Boston Scientific a report on Friday, July 29th. Royal Bank Of Canada restated a "buy" rating and set a $31.00 price target on shares of Boston Scientific Corporation in a report on Tuesday, November 7th. (NYSE:BSX) from a buy rating to a hold rating in a research note issued to investors on Monday morning. Finally, SunTrust Banks, Inc. restated a "buy" rating and issued a $34.00 price target on shares of Boston Scientific Corporation in a research note on Monday, October 2nd.

On October 13 BMO Capital Markets held the company rating at "Buy" targeting a price of $30.00.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider's stock worth $1,077,270,000 after purchasing an additional 38,690,577 shares during the period. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider's stock valued at $294,921,000 after purchasing an additional 8,533,655 shares in the last quarter. Beech Hill Advisors Inc. purchased a new position in shares of Boston Scientific Corporation during the 3rd quarter valued at $353,000. Ubs Asset Management Americas Inc owns 6,074 shares valued at $177,179,000. Its stake was valued at $11,934,000 a decrease of $3,000 as of quarter end.

Citizens Financial Group, Inc. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider's stock valued at $138,928,000 after acquiring an additional 2,850,630 shares in the last quarter. Following the transaction, the executive vice president now directly owns 185,742 shares in the company, valued at approximately $5,100,475.32.

The company's products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.

Other reports by Iphone Fresh

Discuss This Article